Breathing Labs
Home
How To Start
Products
Breathing+ Package
Toys Package
Q&A
Login

Covid19

6Mar

Preprint: Ivermectin was associated with reduced mortality vs Remdesivir

Posted by: admin Categories: Covid19
Comments Off on Preprint: Ivermectin was associated with reduced mortality vs Remdesivir

Our analysis yielded 41,608 patients who had COVID-19 resulting in two unique cohorts that were treated with either Ivermectin (1,072) or Remdesivir (40,536). After using propensity score matching and adjusting for potential confounders, Ivermectin was associated with reduced mortality vs Remdesivir. Preprint: Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of […]

Read more
6Mar

EMR Survey Suggests Ivermectin Associated with Lower Mortality Than Remdesivir

Posted by: admin Categories: Covid19
Comments Off on EMR Survey Suggests Ivermectin Associated with Lower Mortality Than Remdesivir

A team of University of Miami researchers compared fatality rates for COVID-19 patients who took ivermectin and those who took remdesivir and found the ivermectin cohort experienced reduced mortality. “Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir,” the authors wrote. Ivermectin vs. Remdesivir Ivermectin has been discouraged as an […]

Read more
3Mar

Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial

Posted by: admin Categories: Covid19
Comments Off on Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial

Background: The antiviral efficacy of remdesivir in COVID-19 hospitalized patients remains controversial. Objectives: To estimate the effect of remdesivir in blocking viral replication. Methods: We analysed nasopharyngeal normalized viral loads from 665 hospitalized patients included in the DisCoVeRy trial (NCT04315948; EudraCT 2020-000936-23), randomized to either standard of care (SoC) or SoC + remdesivir. We used […]

Read more
26Feb

Export Policy of Injection Remdesivir & Remdesivir APIs revised to ‘Free’

Posted by: admin Categories: Covid19
Comments Off on Export Policy of Injection Remdesivir & Remdesivir APIs revised to ‘Free’

Notification No. 56/2015-2020 Dated February 24th, 2022 The Directorate General of Foreign Trade (DGFT) has amended the export policy of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API), Amphotericin-B injections, Enoxaparin (Formulation and API) and Intra-Venous Immunoglobulin (IVIG) (Formulation and API). Now, the export policy has been revised to ‘Free’ from existing policy of ‘Restricted’ […]

Read more
26Feb

DGFT notifies amendment in export policy of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API).

Posted by: admin Categories: Covid19
Comments Off on DGFT notifies amendment in export policy of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API).

The Directorate General of Foreign Trade vide its notification dated 24th February 2022 has removed export curbs on Remdesivir Injection and its active pharmaceutical ingredients (APIs). Earlier, the department restricted the export of  injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API), drug which is used in COVID-19 treatment. However due the decline in covid-19 case, […]

Read more
25Feb

Restriction on Export of Remdesivir Injection and API removed

Posted by: admin Categories: Covid19
Comments Off on Restriction on Export of Remdesivir Injection and API removed

The export policy of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API), Amphotericin – B injections, Enoxaparin (Formulation and API) and Intra-Venous Immunoglobulin (IVIG) (Formulation and API) falling under HS code as mentioned above or falling under any other HS code has been made ‘Free’ with immediate effect. MINISTRY OF COMMERCE AND INDUSTRY(Department of Commerce)(DIRECTORATE […]

Read more
25Feb

Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients

Posted by: admin Categories: Covid19
Comments Off on Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients

Remdesivir (RDV) reduces time to clinical improvement in hospitalized COVID -19 patients requiring supplemental oxygen. Dexamethasone improves survival in those requiring oxygen support. Data is lacking on the efficacy of combination therapy in patients on mechanical ventilation. We analyzed for comparative outcomes between Corticosteroid (CS) therapy with combined Corticosteroid and Remdesivir (CS-RDV) therapy. We conducted […]

Read more
24Feb

Ministry issues new treatment regimen following increase in Covid-19 children | Health

Posted by: admin Categories: Covid19
Comments Off on Ministry issues new treatment regimen following increase in Covid-19 children | Health

The Ministry of Health added the antiviral drug Remdesivir to the treatment of Covid-19 for children In this new regimen, the Ministry of Health added the antiviral drug Remdesivir to the treatment of Covid-19 for children. Accordingly, Remdesivir is indicated for the treatment of mild inpatients with premature birth, obesity, diabetes, genetic diseases, metabolic disorders, […]

Read more
23Feb

Acute generalized exanthematous pustulosis following treatment with remdesivir in a patient with SARS-CoV-2 infection, a case report

Posted by: admin Categories: Covid19
Comments Off on Acute generalized exanthematous pustulosis following treatment with remdesivir in a patient with SARS-CoV-2 infection, a case report

Acute generalized exanthematous pustulosis following treatment with remdesivir in a patient with SARS-CoV-2 infection, a case report Abstract We hereby, present the first case of Acute generalized exanthematous pustulosis (AGEP) following treatment with remdesivir in a patient with COVID-19 without hydroxychloroquine use which serves as a reminder for considering remdesivir as a possible causative agent […]

Read more
19Feb

Two Haitians die in shipwreck in eastern Dominican Republic

Posted by: admin Categories: Covid19
Comments Off on Two Haitians die in shipwreck in eastern Dominican Republic

Two Haitians died and seven have been rescued after the boat they were occupying was shipwrecked in the eastern Dominican Republic, the local Navy reported this Saturday. Both the bodies and the survivors were rescued by fishermen, some 22 nautical miles south of Catalina Island, according to a Navy statement, which did not specify where […]

Read more
15Feb

Complementary approach to controlling the development of symptomatic COVID-19

Posted by: admin Categories: Covid19
Comments Off on Complementary approach to controlling the development of symptomatic COVID-19

A subcutaneous combination therapy (REGEN-COV, Regeneron Pharmaceuticals) consisting of 2 neutralizing human sequence neutralizing monoclonal antibodies, i.e. subcutaneous casirivimab and imdevimab, reduced the incidence of symptomatic COVID-19 among newly exposed asymptomatic individuals, according to the authors of a multicenter study. Meagan P. O’Brien, MD, of Regeneron Pharmaceuticals, and lead author of the study, reported the […]

Read more
14Feb

Complementary approach to control development of symptomatic COVID-19

Posted by: admin Categories: Covid19
Comments Off on Complementary approach to control development of symptomatic COVID-19

A subcutaneous combination treatment (REGEN-COV, Regeneron Pharmaceuticals) comprised of 2 neutralizing, human sequence monoclonal antibodies, i.e., subcutaneous casirivimab and imdevimab, reduced the incidence of symptomatic COVID-19 among recently exposed, asymptomatic individuals, according to the authors of a multicenter study. Meagan P. O’Brien, MD, from Regeneron Pharmaceuticals, and first author of the study, reported the results […]

Read more
14Feb

WHO grants prequalification of Roche’s Actemra/RoActemra for patients with severe COVID

Posted by: admin Categories: Covid19
Comments Off on WHO grants prequalification of Roche’s Actemra/RoActemra for patients with severe COVID

Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra, as recommended in the global treatment guidelines Read Article The World Health Organization (WHO) has granted prequalification of Actemra/RoActemra (tocilizumab) intravenous (IV) to treat patients with severe COVID-19. Prequalification is a confirmation by WHO that Actemra/RoActemra […]

Read more
13Feb

In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.

Posted by: admin Categories: Covid19
Comments Off on In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.

%PDF-1.5 % 1 0 obj >/Metadata 428 0 R/Pages 2 0 R/StructTreeRoot 3 0 R/Type/Catalog>> endobj 428 0 obj >stream 2022-02-04T13:05:51-05:00 2022-02-12T17:07:30-08:00 2022-02-12T17:07:30-08:00 application/pdf In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance. uuid:1190bf47-1dd2-11b2-0a00-0c09278d5b00 uuid:1190bf4e-1dd2-11b2-0a00-1e0000000000 endstream endobj 2 0 obj > endobj 3 0 obj > endobj 55 0 obj > endobj 56 0 […]

Read more
11Feb

Casirivimab And Imdevimab Drug Interactions Study

Posted by: admin Categories: Covid19
Comments Off on Casirivimab And Imdevimab Drug Interactions Study

Regen-Cov (Casirivimab and Imdevimab Injection): Uses Study Details: Imdevimab: Each 11.1 mL of solution contains 1,332 mg of imdevimab, L-histidine (8.3 mg), L-histidine monohydrochloride monohydrate (12.1 mg), polysorbate 80 (11.1 mg), sucrose (888 mg), and Water for Injection, USP. The pH is 6.0. REGEN-COV (casirivimab and imdevimab solution) injection is a sterile, preservative-free, clear to […]

Read more
10Feb

Solidarity Trial Remdesivir Study

Posted by: admin Categories: Covid19
Comments Off on Solidarity Trial Remdesivir Study

Remdesivir: From Ebola to COVID-19 Study Details: Over the past months a series of studies, summarized by Eastman et al. , have been launched to investigate the effectiveness of remdesivir, alone or in combination with other drugs, against COVID-19, including the WHO SOLIDARITY trial, a four-arm trial comparing remdesivir, lopinavir/ritonavir, lopinavir/ritonavir with interferon beta-1a, and […]

Read more
10Feb

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa

Posted by: admin Categories: Covid19
Comments Off on Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa

% of patients requiring mechanical ventilation  42  34  49  Triangular  [8, 12, 13, 15]  Days of hospitalization for nonventilated patients   15  5  18  Triangular    Days of hospitalization for ventilated patients   19  13  32  Triangular    Efficacy  Base  Low  High  Distribution  Source  Reduced days of hospitalization with remdesivir (from 15 days to 10 […]

Read more
10Feb

Unit 2 Assessment.docx – The interventional study conducted by Spinner et al. aimed to evaluate the efficacy of remdesivir for patients hospitalized

Posted by: admin Categories: Covid19
Comments Off on Unit 2 Assessment.docx – The interventional study conducted by Spinner et al. aimed to evaluate the efficacy of remdesivir for patients hospitalized

The interventional study conducted by Spinner et al. aimed to evaluate the efficacy of remdesivir for patients hospitalized with moderate coronavirus disease, specifically in comparison to standard care. The primary endpoint – assessing the proportion of hospitalized patients discharged by day 14 of the study – was determined in advance. However, as patients were enrolled […]

Read more
9Feb

Success rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center

Posted by: admin Categories: Covid19
Comments Off on Success rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center

J Family Med Prim Care. 2021 Nov;10(11):4236-4241. doi: 10.4103/jfmpc.jfmpc_578_21. Epub 2021 Nov 29. ABSTRACT INTRODUCTION: After the first case of Covid-19 was identified in Wuhan City, China, the numbers increased rapidly all over the world putting a huge burden on the entire healthcare system. Managing these cases posed a great challenge to the treating clinicians […]

Read more
« Older posts